Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has reiterated an Overweight rating on Regeneron Pharmaceuticals, maintaining a price target of $1200.
September 23, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal has reiterated an Overweight rating on Regeneron Pharmaceuticals, maintaining a price target of $1200.
The reiteration of an Overweight rating and a high price target of $1200 by a major financial institution like Wells Fargo is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100